The nationwide longitudinal Swedish SWEDEHEART registry presented a substantial reduction in 1-year mortality of myocardial infarction (MI) from 1995 to 2014, with the gradual widespread implementation of new evidence-based treatment strategies including reperfusion, primary percutaneous coronary intervention, dual antiplatelet therapy, statins, beta-blockers, and angiotensin-converting-enzyme/angiotensin-2-receptor inhibitors 2, 3. The gene discussed is AGTR2; the disease is myocardial infarction.